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Abstract
Background: Family history (FH) by different relative types and risk of upper gastrointestinal
(UGI) cancers has been only rarely reported; the data on UGI cancer survival are sparse.
Methods:  600 esophageal squamous cell carcinoma (ESCC) cases, 598 gastric cardia
adenocarcinoma cases, and 316 gastric non-cardia adenocarcinoma cases, and 1514 age-, gender-,
and neighborhood-matched controls were asked for FH in first degree relatives and non-blood
relatives. Odds ratios (ORs) and 95% confidence intervals (CIs) from logistic regressions, and
hazard ratios (HRs) from Cox proportional hazard regressions were estimated.
Results: Increased ESCC risk was associated with FH of any cancer (OR = 1.72, 95% CI = 1.39–
2.12), FH of any UGI cancer (OR = 2.28, 95%CI = 1.77–2.95) and FH of esophageal cancer (OR =
2.84, 95%CI = 2.09–3.86), but not FH of non-UGI cancer. Individuals with two or more affected
first-degree relatives had 10-fold increased ESCC risk. FH of gastric cardia cancer was associated
with an increased risk of all three cancers. Cancer in non-blood relatives was not associated with
risk of any UGI cancer. FH of UGI cancer was associated with a poorer survival rate among younger
ESCC cases (HR = 1.82, 95%CI = 1.01–3.29).
Conclusion:  These data provide strong evidence that shared susceptibility is involved in
esophageal carcinogenesis and also suggest a role in prognosis.
Background
Esophageal cancer is the sixth most common cause of can-
cer death worldwide and the fourth most common malig-
nancy in China [1]. Shanxi Province in north central
China has among the highest esophageal cancer rates in
the world [2]. Esophageal cancers in Shanxi are predomi-
nantly squamous cell carcinomas and adenocarcinomas
are rare. The disease progresses rapidly; even when the
tumors are surgically removed, the 5-year survival rate is
less than 18% http://www.cancer.org/docroot/cri/con
tent/
cri_2_4_1x_what_are_the_key_statistics_for_esophagus_
cancer_12.asp. However, the etiology of this disease is still
largely unknown.
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Studies have implicated a number of environmental expo-
sures and predisposing conditions, predominantly
tobacco smoking and alcohol drinking as risk factors of
esophageal cancer in the Western world [3-5], although
risk from these factors is either small or null in the espe-
cially high-risk populations of China and Iran [6-8].
Inherited susceptibility is also a very important factor in
esophageal carcinogenesis, as suggested by familial aggre-
gation [9-13], family history (FH) of cancer [3,14-19], seg-
regation studies [20,21], and candidate gene association
studies [22-25]. However, co-occurrence of esophageal
cancer among family members does not necessarily reflect
shared genetic susceptibility; it could also be due to
shared environmental exposures. Therefore, studying dif-
ferent types of relatives (blood and non-blood relatives
sharing household) might provide information to help
differentiate genetic and environmental components in
esophageal pathogenesis. To date, systematic exploration
for the role of FH by relative type in esophageal cancer
development has rarely been reported [16].
It has been suggested that familial esophageal cancer may
develop earlier and have a poorer prognosis than sporadic
esophageal cancer [26]. Therefore, it is reasonable to
hypothesize that FH of cancer might also predict survival
of upper gastrointestinal (UGI) cancer. The limited data
available on esophageal cancer[26], gastric cancer [27,28]
and colorectal cancer[29] on this are, however, inconclu-
sive.
To examine the role of FH in esophageal cancer, we took
advantage of a case-control study conducted in Shanxi,
where the rates for both esophageal squamous cell carci-
noma and gastric cardia adenocarcinoma are among the
highest in the world [2]. Cancers at these two sites share
some etiologic risk factors, and historically were diag-
nosed as a single disease referred as "hard swallowing dis-
ease" [30]. Therefore, we also evaluated the association
between FH of cancer and gastric cancer risk, including
gastric cardia cancer and gastric noncardia cancer. In addi-
tion, we examined the survival status of UGI cancer
patients in relation to FH of UGI cancer.
Methods
Patients presenting to the Shanxi Cancer Hospital in Taiy-
uan, Shanxi, People's Republic of China between 1997
and 2005 were potentially eligible for inclusion in this
case-control study of upper gastrointestinal (UGI) tract
cancers. The Shanxi Cancer Hospital, the largest cancer
hospital in Shanxi, performed surgery on approximately
2000 new esophageal and 1800 new gastric cancers annu-
ally during the study period. We included cases in this
study who: (i) were males or females 20 years of age or
older, (ii) resided in one of five geographic regions in rel-
atively close proximity to the hospital (Taiyuan, Linfen,
Jinzhong, Chanzi, and Xinzhou), (iii) had newly diag-
nosed (incident) cancer of the esophagus or stomach
without previous treatment (ie, no surgery, chemother-
apy, or radiotherapy), (iv) underwent complete surgical
resection of their tumors (ie, either esophagectomy or gas-
trectomy with curative intent, without neoadjuvant or
adjuvant therapy) at the Shanxi Cancer Hospital, and (v)
had their diagnosis histologically confirmed. During the
study period, about two-thirds of new UGI cancers pre-
senting to the Shanxi Cancer Hospital came from the five
geographic regions we designated. Since one objective of
our study was to evaluate somatic changes in tumors in
UGI cancer cases, we limited recruitment to patients who
had surgical resection of their tumor as their primary ther-
apy. We invited a systematic sample (eg, all patients from
selected days of selected weeks) of new UGI cancer
patients from our designated geographic regions who
underwent surgical resection (approximately 50% of such
patients from these regions) to join the study; 98% of
invitees accepted enrollment in the study.
Esophageal cancer cases were limited to those with histo-
logical esophageal squamous cell carcinoma (ESCC),
which included nearly all esophageal cancers since aden-
ocarcinoma of the esophagus is essentially nonexistent in
this high-risk population. Gastric cardia adenocarcinoma
(GCA) included adenocarcinomas located in the top three
centimeters of the stomach, while gastric non-cardia ade-
nocarcinoma (GNCA) included gastric cancers located in
the remainder of the stomach. All histological diagnoses
were made initially by pathologists at the Shanxi Cancer
Hospital and confirmed by pathologists at the National
Cancer Institute.
One control was enrolled for each case matched on age (±
5 years), gender, and neighborhood of residence. To iden-
tify potential controls, each case was asked to identify a
neighbor of approximately the same age and gender.
When the initial suggested neighbor could not be enrolled
(i.e., unavailable, ineligible, or refused), other neighbors,
or the village doctor were asked to suggest another neigh-
bor of the same age and gender. Potential controls were
asked if they had any cancer or UGI disease, and were con-
sidered ineligible if they reported affirmatively to either
question. In addition, the interview for the control had to
be completed within six months of its matched case to be
included. Over 75% of all identified potential controls
were enrolled, including 95% of available and eligible
controls (i.e., the ones actually invited). The primary rea-
son for non-enrollment among available/eligible controls
was refusal to give a blood sample.
After obtaining informed consent, both cases (in hospital)
and controls (at home) were interviewed to obtain infor-
mation on demographic characteristics, lifestyle, and FH.BMC Cancer 2009, 9:269 http://www.biomedcentral.com/1471-2407/9/269
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Questionnaire-based information on occupation, educa-
tion, tobacco smoking, alcohol use, and FH of cancer,
were collected. For FH of cancer, questions were asked
about any malignant tumor in first degree relatives,
including father, mother, siblings, and offspring. In addi-
tion, information on cancer history was also collected on
non-blood relatives in the same household as the cases
and controls (i.e., spouses, adopted parents, step-parents,
and adopted siblings).
In addition to information collected at the time of recruit-
ment, cancer cases (or their immediate family) were re-
contacted by study research nurses to determine their vital
status and inquire about post-surgical treatment (i.e.,
chemotherapy, radiotherapy, traditional Chinese herbs,
and other treatment) through the end of 2005. Deaths
were recorded; cases still alive were censored as of the date
of their last contact.
Since there were no malignant tumors reported in off-
spring, analyses of FH in first degree relatives were
restricted to FH in father, mother, and siblings (both full
and half -sibling). When numbers permitted, FH of
esophageal cancer among first degree relatives was also
examined separately by relation type (i.e., mother, father,
and siblings). Cancers in spouses and other non-blood
relatives in the same household were uncommon and
were combined into a single group (i.e., non-blood rela-
tive) for analyses. The frequency distribution of siblings
was the same for ESCC, GCA, and GNCA cases, and con-
trols (median = 3, inter-quartile range = 2–5).
Odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated from logistic regressions. We confirmed
that the three controls groups (for ESCC, GCA, and
GNCA, respectively) did not differ significantly by the dis-
tribution of FH of cancer. To optimize power, all analyses
used unconditional logistic regression adjusted for match-
ing factors and pooled all controls. Geographic region was
used as a surrogate for the neighborhood matching factor
in unconditional logistic regression models. Adjustment
for tobacco smoking, alcohol consumption, occupation,
source of drinking water, scalding-hot food consumption,
tea consumption, and number of siblings did not modify
the results substantially. In particular, the ORs for ever
tobacco smoking were 1.19 (95% CI 0.84–1.69), 0.80
(95% CI 0.60–1.06), and 1.12 (95% CI 0.74–1.69) for
ESCC, GCA and GNCA respectively. Furthermore, the ORs
for ever alcohol drinking were 1.18 (95% CI 0.93–1.50),
0.90 (95% CI 0.80–1.23), and 1.24 (95% CI 0.93–1.67)
for ESCC, GCA and GNCA respectively. Therefore, only
results adjusted for the matching factors (age, gender, and
geographic region) are reported.
Hazard ratios (HRs) and 95% CIs from Cox proportional
hazard regressions were calculated to estimate the associ-
ation of FH in first degree relatives and survival time from
UGI cancers. Survival time was calculated as days from
UGI cancer surgery to death or date of last contact. Sur-
vival analyses were adjusted for matching factors and clin-
ical characteristics of the tumor, including histological
grade (well differentiated: G1 and G2; poor differentiated:
G3 and G4), tumor stage (early: TIS, T1, and T2; late: T3
and T4) and lymph node metastasis (yes vs. no). In addi-
tion, we also conducted analyses by further adjusting for
post-surgical treatment. Finally, we examined the ESCC
survival in all cases, cases <50 years, and cases ≥50 years
by family history of UGI cancer using Kaplan-Meier plots.
All analyses were two-sided, and statistical significance
was defined as a P-value less than 0.05.
The study was approved by the institutional review boards
of the Shanxi Cancer Hospital in Taiyuan, and the
National Cancer Institute in Bethesda, Maryland.
Results
A total of 600 ESCC, 598 GCA, and 316 GNCA cases, and
1514 age-, gender-, and neighborhood- matched controls
were included in these analyses. All cases were histologi-
cally confirmed. Among the cases, 32 ESCC, 70 GCA, and
21 GNCA cases did not have follow-up data, resulting in
568 ESCC, 529 GCA, and 295 GNCA cases available for
the survival analyses. Gender, age, and geographic region
distributions of study subjects are shown in Table 1. Clin-
ical characteristics of the cases available for the survival
analyses are shown in Table 2. Overall, nearly three-quar-
ters of cases were males, and the median age at diagnosis
was 59 years. Most cancer cases were diagnosed at late
stage. The median follow-up time was about 3 years and
median survival time after surgery was about 2 years.
FH of any malignant tumor and risk of UGI cancer
Subjects (i.e., cases and controls) reported the occurrence
of 58 different types of malignant tumors in their family
members. A FH of any malignant tumor in a first degree
relative was associated with 1.72, 1.32, and 1.52-fold
increased risks of ESCC, GCA, GNCA respectively (Table
3). Though not significant, the associations appeared
stronger in males and younger persons (<50 years). Sub-
jects with more than one cancer-affected first degree rela-
tive had higher risks of UGI cancers than those with only
one affected relative (P trend < 0.01 each for ESCC, GCA,
and GNCA). Cancers in non-blood relatives were not
associated with risk of any of the UGI cancers evaluated
here.
FH of UGI cancer and risk of UGI cancer
FH of any UGI cancer was associated with 2.28, 1.62, and
1.65-fold increased risks of ESCC, GCA, and GNCA (Table
3). Neither age nor gender modified these associations.
Having two or more affected relatives showed higher risksBMC Cancer 2009, 9:269 http://www.biomedcentral.com/1471-2407/9/269
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of all three UGI cancers. In contrast, any UGI cancer in
non-blood relatives was not associated with increased risk
of ESCC, GCA, or GNCA.
FH of esophageal cancer was associated with an increased
risk of ESCC, but not GCA or GNCA overall. However,
increased risk for GCA and GNCA was observed among
persons with more esophageal cancer-affected relatives.
Though FH of gastric cardia cancer was associated with
increased risk for all three UGI cancers (GCA, ESCC, and
GNCA), FH of gastric noncardia cancer was not associated
with risk of any UGI cancers evaluated.
FH of non-UGI cancer in either first degree relatives or
non-blood relatives was not associated with risk of ESCC,
GCA, and GNCA.
FH of esophageal cancer by relative type and risk of UGI 
cancer
FH of esophageal cancer in first degree relatives was asso-
ciated with a 2.84-fold increase of ESCC risk (Table 3).
Neither age (P interaction = 0.91) nor gender (P interac-
tion = 0.23) modified this association. While individuals
with one affected first degree relative had a 2.53-fold
increased risk of ESCC (95% CI = 1.84–3.50), those with
two or more affected first degree relatives had a 10.0-fold
increased ESCC risk (95% CI = 3.24–31.2) (P trend <
0.01). The ESCC odds ratios associated with father,
mother, and sibling histories of esophageal cancer were
2.01, 3.27, and 4.66, respectively. The risk of GCA (P
trend = 0.02) and GNCA (P trend = 0.03) increased
monotonically with greater numbers of affected relatives.
No association was seen between esophageal cancer in
non-blood relatives and risk of ESCC, GCA, or GNCA.
FH of malignant tumor and survival from UGI cancer
We did not observe significant associations between FH of
any malignant tumor, any UGI cancer, or esophageal can-
cer, gastric cardia cancer, and gastric noncardia cancer in
first degree relatives and survival from ESCC, GCA, and
GNCA (Table 4). Though not significant, there was a sug-
gestion of longer survival in GCA cases with a positive FH.
Table 1: Selected demographic characteristics of UGI cancer cases and controls
Controls
(N = 1514)
ESCC
(N = 600)
GCA
(N = 598)
GNCA
(N = 316)
Gender Male (%) 1107(73) 376(63) 491(82) 239(76)
Female (%) 407(27) 224(37) 107(18) 77(24)
Age (median, inter-quartile) (years) 59(52–65) 58(51–64) 61(55–66) 57.5(50–63)
Male 60(53–65) 59 (52–64) 61.5(55–66) 58(51–63)
Female 57(50–63) 57(50.5–63) 60(54–64) 54(44–63)
Geographic regions Taiyuan (%) 524(35) 212(35) 199(33) 113(36)
Linfen (%) 266(18) 94(16) 118(20) 54(17)
Jinzhong (%) 294(19) 153(26) 104(18) 37(12)
Chanzi (%) 274(18) 90(15) 121(20) 63(20)
Xinzhou (%) 156(10) 51(8) 56(9) 49(15)
Table 2: Selected clinical characteristics of UGI cancer cases
ESCC
(N = 568)
GCA
(N = 529)
GNCA
(N = 295)
Survival status Deceased 345(61) 378(71) 194(66)
Censored 223(39) 155(29) 101(34)
Histological grade Well differentiated (G1 or G2) 450(79) 186(35) 78(27)
Poor differentiated (G3 or G4) 118(21) 341(65) 215(73)
Primary tumor stage Early(TIS or T1 or T2) 95(17) 26(5) 33(11)
Late(T3 or T4) 473(83) 502(95) 261(89)
Lymph node metastasis No 330(58) 140(27) 80(27)
Yes 238(42) 386(73) 213(73)
Survival days from surgery Median (inter quartile) 794(356–1979) 622(314–1606) 615(256–2147)BMC Cancer 2009, 9:269 http://www.biomedcentral.com/1471-2407/9/269
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Table 3: Risk of UGI cancer by FH of malignant tumor in first degree relatives and non-blood relatives*
ESCC GCA GNCA
FH Control (%) Case (%) OR (95% CI) Case (%) OR (95% CI) Case (%) OR (95% CI)
Any malignant tumor
First degree relative 334(22) 197(33) 1.72(1.39–2.12) 162(27) 1.32(1.06–1.64) 94(30) 1.52(1.15–1.99)
1 affected 294(19) 160(27) 1.58(1.26–1.98) 135(22) 1.25(0.99–1.58) 79(25) 1.43(1.07–1.92)
≥ 2 affected 40(3) 37(6) 2.76(1.73–4.40) 27(5) 1.83(1.10–3.03) 15(5) 2.15(1.16–3.98)
P trend <0.001 0.005 0.001
Male 233(21) 126(34) 2.00(1.50–2.54) 132(27) 1.35(1.05–1.73) 78(33) 1.83(1.34–2.49)
Female 101(25) 71(32) 1.40(0.98–2.02) 30(28) 1.24(0.76–2.01) 16(21) 0.81(0.44–1.48)
< 50 yr 59(22) 41(38) 2.17(1.32–3.56) 22(33) 1.95(1.06–3.58) 28(36) 2.39(1.35–4.25)
≥ 50 yr 275(22) 156(32) 1.61(1.27–2.04) 140(26) 1.25(0.98–1.58) 66(28) 1.35(0.98–1.85)
Non-blood relative 58(4) 26(4) 1.08(0.66–1.76) 25(4) 1.02(0.62–1.66) 6(2) 0.61(0.26–1.46)
Any UGI cancer
First degree relative 170(11) 131(22) 2.28(1.77–2.95) 104(17) 1.62(1.24–2.12) 53(17) 1.65(1.17–2.33)
1 affected 162(11) 114(19) 2.08(1.59–2.71) 88(15) 1.43(1.08–1.90) 46(14) 1.50(1.05–2.15)
≥ 2 affected 8(1) 17(3) 6.37(2.82–15.6) 16(3) 5.35(2.26–12.7) 7(2) 4.78(1.68–13.6)
P trend <0.001 <0.001 0.001
Male 124(11) 88(23) 2.59(1.90–3.54) 87(18) 1.66(1.23–2.23) 45(19) 1.89(1.29–2.77)
Female 46(11) 43(19) 1.85(1.16–2.92) 17(16) 1.52(0.82–2.80) 8(10) 0.98(0.43–2.20)
< 50 yr 34(12) 23(21) 1.84(1.01–3.35) 10(15) 1.23(0.56–2.68) 17(22) 2.34(1.18–4.65)
≥ 50 yr 136(11) 108(22) 2.37(1.78–3.16) 94(18) 1.70(1.28–2.27) 36(15) 1.51(1.01–2.26)
Non-blood relative 26(2) 12(2) 1.11(0.54–2.24) 13(2) 1.17(0.59–2.32) 3(1) 0.73(0.22–2.45)
Esophageal cancer
First degree relative 97(6) 95(16) 2.84(2.09–3.86) 52(9) 1.34(0.94–1.91) 28(9) 1.56(0.99–2.43)
1 affected 93(6) 83(14) 2.53(1.84–3.50) 43(7) 1.15(0.79–1.68) 25(8) 1.44(0.90–2.30)
≥ 2 affected 4(0.3) 13(2) 10.0(3.24–31.2) 9(2) 5.75(1.74–19.0) 3(1) 4.54(0.96–21.6)
P trend <0.001 0.022 0.026
Father 52(3) 40(7) 2.01(1.31–3.10) 23(4) 1.06(0.64–1.76) 13(4) 1.27(0.68–2.38)
Mother 29(2) 34(6) 3.27(1.96–5.47) 19(3) 1.69(0.93–3.07) 14(4) 2.52(1.30–4.89)
Sibling 21(1) 35(6) 4.66(2.67–8.13) 20(3) 2.36(1.26–4.41) 4(1) 1.14(0.38–3.40)
Non-blood relative 9(0.6) 7(1) 1.86(0.68–5.10) 6(1) 1.49(0.52–4.26) 1(0.3) 0.76(0.09–6.16)
Gastric cardia cancer 25(2) 23(4) 2.45(1.37–4.39) 28(5) 2.87(1.65–5.00) 12(4) 2.35(1.16–4.79)
Gastric noncardia cancer 51(3) 19(3) 0.95(0.56–1.64) 31(5) 1.54(0.97–2.44) 17(5) 1.52(0.86–2.69)
Any non- UGI tumor
First degree relative 164(11) 66(11) 0.98(0.72–1.33) 58(10) 0.92(0.67–1.27) 41(13) 1.22(0.84–1.76)
Non-blood relative 32(2) 14(2) 1.05(0.55–2.01) 12(2) 0.90(0.46–1.77) 3(1) 0.54(0.16–1.80)
*The reference group for each analysis, the group of individuals with negative family history, is omitted from this table;
ORs adjusted for age, gender, and geographic region; First degree relatives: father, mother, and siblings; Non-blood relatives: spouse, adopted or 
step-parents, and adopted brotherBMC Cancer 2009, 9:269 http://www.biomedcentral.com/1471-2407/9/269
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The relation of FH to survival was modified by age (P
interaction = 0.01) (Figure 1) such that younger (<50
years) ESCC cases with a positive FH had poorer survival
(Figure 2), but not older cases (Figure 3); median survival
for FH positive ESCC cases was 473 days versus 712 days
for FH negative cases. A similar age-related pattern was
also observed for GCA cases (P interaction = 0.06). FH of
non-UGI cancer was associated with increased death rate
for GNCA (HR = 1.73, 95% CI = 1.16–2.60).
In addition, we also conducted analyses by further adjust-
ing for post-surgical treatment. However, the results were
not substantially modified: HRs of ESCC, GCA, and
GNCA cases with FH of any UGI cancer were 1.04(0.80–
1.34), 0.82(0.62–1.08), and 0.84(0.56–1.26) respec-
tively; HRs of ESCC, GCA, and GNCA cases with FH of
esophageal cancer were 0.96(0.71–1.28), 0.81(0.56–
1.18), and 1.05(0.65–1.72), respectively. Therefore, only
results without post-surgical treatment adjustment were
reported.
Discussion
In this large case-control study focusing on FH of malig-
nant tumors and risk of UGI cancers, we observed
increased risk for ESCC among individuals with FH of any
malignant tumor, any UGI cancer, and esophageal cancer.
The association strengthened as FH became more organ-
specific, and was strongest for a FH of esophageal cancer.
FH of non-UGI cancer was not associated with ESCC risk,
suggesting that the increased risk for FH of any malignant
tumor was due to UGI cancer. Risk also increased with
greater number of affected relatives. While FH of gastric
cardia cancer was associated with an elevated risk of
ESCC, GCA, and GNCA, FH of gastric noncardia cancer
did not affect risk. Notably, cancers in non-blood relatives
were not associated with risk of any UGI cancers evalu-
ated. FH did not predict prognosis among cases overall,
but was suggestively associated with reduced death rate
from GCA, and younger ESCC cases with a FH of UGI can-
cer experienced poorer survival.
The positive association between FH of esophageal cancer
and ESCC risk in the current study is consistent with pre-
vious reports [3,6,14-16,19,31-36], and suggests shared
susceptibility, including both genetic and environmental
factors, in esophageal cancer pathogenesis.
Aggregation of cancer among non-blood relatives in the
same household, like wives and husbands, supports envi-
ronmental compared to genetic factors in cancer etiology.
A cohort study from Japan examined the correlation
between questionnaire-based history of cancer in fathers
and mothers of cohort members, and observed more par-
ent pairs with esophageal cancer, as well as stomach can-
Table 4: FH of malignant tumor in first degree relatives and survival from UGI cancer *
ESCC GCA GNCA
FH Case Death HR (95% CI) Case Death HR (95% CI) Case Death HR (95% CI)
Any malignant tumor - 379 232 1 384 278 1 210 134 1
+ 190 113 1.09(0.86–1.36) 146 96 0.80(0.63–1.01) 85 60 1.22(0.88–1.68)
Any UGI cancer - 443 268 1 434 309 1 245 164 1
+ 126 77 1.06(0.82–1.38) 96 65 0.82(0.62–1.08) 50 30 0.85(0.56–1.28)
0 affected - 443 268 1 434 309 1 245 164 1
1 affected + 109 69 1.15(0.88–1.50) 82 55 0.80(0.60–1.07) 43 23 0.73(0.46–1.15)
≥2 affected + 17 8 0.64(0.32–1.30) 14 10 0.94(0.48–1.84) 7 7 1.82(0.84–3.97)
<50 + 23 19 1.82(1.01–3.29) 8 7 2.30(0.85–6.20) 16 8 0.96(0.38–2.38)
>=50 + 103 58 0.92(0.68–1.22) 88 58 0.76(0.57–1.02) 34 22 0.78(0.49–1.26)
Esophageal cancer - 479 291 1 481 342 1 268 174 1
+ 90 54 0.97(0.72–1.31) 49 32 0.81(0.56–1.18) 27 20 1.03(0.63–1.68)
Gastric cardia cancer - 546 327 1 504 356 1 284 189 1
+ 23 18 1.61(0.99–2.61) 26 18 0.88(0.54–1.42) 11 5 0.66(0.26–1.64)
Gastric noncardia cancer - 550 336 1 503 356 1 279 185 1
+ 19 9 0.80(0.41–1.56) 27 18 0.76(0.47–1.22) 16 9 0.96(0.48–1.91)
Non-UGI cancer - 505 309 1 480 343 1 260 164 1
+ 64 36 1.10(0.77–1.56) 50 31 0.82(0.56–1.20) 35 30 1.73(1.16–2.60)
*HRs adjusted for age, gender, geographic region, histologic grade, primary tumor stage, and lymph node metastatsisBMC Cancer 2009, 9:269 http://www.biomedcentral.com/1471-2407/9/269
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cer, than expected [37], consistent with a role for
environmental factors in these cancers. In contrast, a case-
only study of esophageal cancer that examined FH of
esophageal cancer by relative type found more esophageal
cancer patients among blood relatives than non-blood rel-
atives [17]. Our findings are more consistent with the lat-
ter study since we found significant effects only for blood
relatives. Further, the stronger ORs and dose response pat-
tern seen for multiple affected relatives suggests a role for
genetic susceptibility in etiology[6]. Since we have no
information on environmental exposures in blood or
non-blood relatives, we can not evaluate environmental
factors in the observed familial aggregation.
The ESCC risk estimates showed consistent increases with
FH of esophageal cancer in fathers, mothers, or siblings in
the current study, with the strongest association with sib-
lings. Our risk estimate for sibling history was nearly iden-
tical to the report of Garavello et.al. (OR = 4.6, 95% CI =
1.2–17.4).13, and is consistent with recessive heredity, or
a gene dose effect involved in the pathogenesis of esopha-
geal cancer [38]. However, we can not exclude the possi-
bility of shared environment exposures in childhood [39],
a critical period for cancer development.
Some studies suggest that FH increases the risk of cancer
at many sites and is not site-specific [40]. The association
between FH and ESCC risk in our study strengthened as
FH became more specific: OR = 1.48 for FH of any cancer,
OR = 1.66 for FH of any UGI cancer, and OR = 1.99 for FH
of esophageal cancer. In contrast, no association was
observed between FH of non-UGI cancer and risk of
ESCC. This suggests that the shared susceptibility is UGI-
specific, predominantly esophagus-specific, and FH of
non-UGI cancer is not important for UGI cancer risk pre-
diction in this population. A similar pattern was observed
for risk of GCA and GNCA.
ESCC survival in cases by FH of UGI cancer Figure 1
ESCC survival in cases by FH of UGI cancer. Log-Rank 
test P = 0.7286
ESCC survival in cases by FH of UGI cancer < 50 years old Figure 2
ESCC survival in cases by FH of UGI cancer < 50 
years old. Log-Rank test P = 0.0.0228
ESCC survival in cases by FH of UGI cancer ≥ 50 years old Figure 3
ESCC survival in cases by FH of UGI cancer ≥ 50 
years old. Log-Rank test P = 0.4829BMC Cancer 2009, 9:269 http://www.biomedcentral.com/1471-2407/9/269
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Younger age at onset is often taken to suggest a genetic
role in disease. In a previous case-control study [26], FH
correlated with early age of onset for esophageal cancer.
Similarly, a small case-control study reported higher risk
among younger people who had a FH [16]. We explored
age at onset but were not able to detect any significant age
effects.
The majority of previous studies reported increased risk of
gastric cancer among people with a positive FH [15,41-
50]. In the only two studies that examined the risk of gas-
tric cancer by anatomic sub sites (cardia and non-cardia)
[47,50], FH of gastric cancer was associated with increased
risk of non-cardia cancer only [50], and FH of any cancer
was associated with increased risk of cardia cancer only
[47]. With more detailed information in the current study,
we observed that FH of gastric cardia cancer was associ-
ated with increased risk for GCA as well as GNCA, but no
association was observed between FH of gastric noncardia
cancer and risk of either GNCA or GCA.
Since the esophagus and stomach are anatomically adja-
cent, they may share some common etiological factors.
With the detailed FH information collected here, we were
able, for example, to evaluate FH of esophageal cancer as
a risk factor for both ESCC and GCA, as well as FH of gas-
tric cardia cancer as risk factor for ESCC and GCA. Con-
sistent with previous reports, we did not observe an
overall association between FH of esophageal cancer and
risk of GCA or GNCA [15,42]. However, we observed an
increased risk of GCA and GNCA in persons with more
esophageal cancer-affected relatives, which suggests
shared susceptibility among these cancers. Alternatively,
we cannot rule out misclassification since no FH cancer
reports were confirmed. Two studies that examined the
relationship between FH of gastric cancer and ESCC risk
found null results [15,34]. In contrast, we observed an
increased ESCC risk with FH of gastric cardia cancer but
not FH of non-cardia cancer. Differences from previous
reports could be due to variation in the prevalence of gas-
tric cardia adenocarcinoma in the study populations.
Moreover, even though our study is large, FH was based
exclusively on self reports, and differences could also be
due to miscategorization.
Several lines of evidence support a role of genetics in can-
cer survival: FH of colorectal cancer is associated with
improved survival in stage III colon cancer [29]; gene pol-
ymorphisms have been related to differences in survival of
breast cancer cases [51,52]; and familial UGI cancer cases
have shown higher microsatelite instability [53], greater
loss of heterozygosity [54], and different gene expression
patterns from sporadic cases [55]. Therefore, it is reasona-
ble to hypothesize that FH might affect both risk and
prognosis in UGI cancers. A large study with 1715 ESCC
cases conducted in Hebei by Wen and colleagues found
poorer prognosis in ESCC patients with a FH of UGI can-
cers [26]. Though we did not find an association between
FH of cancer and survival from ESCC overall, survival was
poorer in young cases with a positive FH. These results
were not substantially modified by additional adjustment
for post-surgical treatment. This provides some evidence
that familial esophageal cancers have an altered clinical
course from sporadic cases, an observation which needs
confirmation in other studies.
A number of studies have examined FH in relation to gas-
tric cancer survival [27,28,56,57], but only one reported a
suggestively reduced death rate (HR = 0.82, 95% CI =
0.62–1.08) for cases with a positive FH [27]. We observed
a similar, statistically insignificant, reduced death rate
(HR = 0.82, 95% CI = 0.62–1.08) in GCA cases, but not
GNCA cases. These suggestions of improved survival sta-
tus among GCA cases may indicate the existence of differ-
ent pathways for the progression of familial cancer from
sporadic cancer. Though the reason is unclear, we also
observed an increased death rate among GNCA cases with
a FH of non-UGI cancer.
There are several advantages to our study: large sample
size, high participation rates for cases (100%) and con-
trols (95%), high follow-up rate (over 90%), neighbor-
hood-matched controls, detailed information on FH of
any malignant tumor, and cancer information from non-
blood relatives. These advantages allowed us to explore
site-specific familial aggregation of cancer and differenti-
ate roles of genetic and environmental factors in UGI can-
cer development. Limitations of this study are: potential
recall bias due to the nature of the case-control study
design, under-ascertainment of FH, limited confirmation
of cancer reports from relatives, potential misclassifica-
tion of cancer types in relatives, and limited number of
families with multiple esophageal cancer-affected mem-
bers in ESCC controls, as well as small number of non-
blood relatives with cancers.
Conclusion
In this large study focused on FH and UGI cancer, we
observed an increased ESCC risk among individuals with
a FH of malignant tumors. The association was esopha-
gus-specific, and stronger with multiple affected relatives.
Cancers in non-blood relatives were not associated with
UGI cancer risk. FH of UGI cancer was also associated
with poorer survival rate in young ESCC cases. These data
provide strong evidence that shared genetic susceptibility
is involved in esophageal carcinogenesis and also suggest
a role in prognosis.
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